- Home
- LU vs SNDX Comparison
LU vs SNDX Comparison
Compare LU & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LU | SNDX |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LU | SNDX |
|---|---|---|
| Price | $8.39 | $13.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $23.66 | ★ $37.27 |
| AVG Volume (30 Days) | 1.6M | ★ 2.2M |
| Earning Date | 10-27-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $172,352,000.00 |
| Revenue This Year | N/A | $82.25 |
| Revenue Next Year | N/A | $46.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 627.84 |
| 52 Week Low | $0.83 | $12.80 |
| 52 Week High | $8.49 | $25.59 |
Technical Indicators
Market Signals| Indicator | LU | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 96.16 | 27.08 |
| Support Level | $1.45 | $12.80 |
| Resistance Level | N/A | $18.75 |
| Average True Range (ATR) | 0.13 | 0.65 |
| MACD | 0.74 | -0.11 |
| Stochastic Oscillator | 91.57 | 8.06 |
Price Performance
Historical ComparisonAbout LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is an investment holding company, together with its consolidated subsidiaries, engaged in core retail credit and enablement business to both borrowers and institutions in the People's Republic of China. The group's segments are Lending-related business, which provides Retail credit and enablement, consumer finance loans, and Digital banking business, including Retail banking and SME banking.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.